Management of Bacterial Vaginosis in Patients with a Pessary in Place
Treat bacterial vaginosis in pessary users with standard first-line therapy—oral metronidazole 500 mg twice daily for 7 days—because the pessary itself does not alter treatment efficacy, and removing the pessary is unnecessary for successful antimicrobial therapy. 1
Treatment Approach
First-Line Antimicrobial Regimen
Oral metronidazole 500 mg twice daily for 7 days achieves 95% cure rates and is the preferred regimen for pessary users with bacterial vaginosis, providing systemic coverage that addresses both vaginal and potential subclinical upper genital-tract infection. 1
The pessary does not need to be removed during treatment; standard antimicrobial therapy is effective with the device in place. 2, 1
Patients must abstain from alcohol during metronidazole therapy and for 24 hours after the final dose to prevent disulfiram-like reactions (flushing, nausea, vomiting, headache). 1
Alternative Regimens When Metronidazole Cannot Be Used
Oral clindamycin 300 mg twice daily for 7 days is the preferred alternative for patients with metronidazole allergy or intolerance. 1
Metronidazole vaginal gel 0.75% once daily for 5 days (75–84% cure rate) or clindamycin cream 2% intravaginally at bedtime for 7 days (78–82% cure rate) are acceptable alternatives, though slightly less efficacious than oral metronidazole. 1
Avoid single-dose metronidazole 2 g as first-line therapy because its 84% cure rate is inferior to the 95% cure achieved with the 7-day regimen. 1
Important Counseling Points for Pessary Users
Clindamycin cream and ovules are oil-based and can weaken latex condoms and diaphragms, potentially compromising contraceptive effectiveness. 1
Pessary users have a 3.3-fold increased risk of developing bacterial vaginosis (32% prevalence versus 10% in controls) due to the foreign body effect on vaginal flora. 3
Smoking independently increases bacterial vaginosis risk 2.9-fold in pessary users, creating a compounded risk when both factors are present. 3
Follow-Up and Recurrence Management
Routine follow-up visits are unnecessary if symptoms resolve; instruct patients to return only if symptoms recur. 1
Recurrence is common (50–80% within one year) in all bacterial vaginosis patients, including pessary users. 4
Any CDC-recommended regimen may be used to treat recurrent disease; no long-term maintenance antimicrobial therapy is recommended. 1
Do not routinely treat male sexual partners, as multiple randomized trials demonstrate that partner treatment does not improve cure rates or reduce recurrence in standard bacterial vaginosis management. 1 Note: A 2025 trial 5 showed benefit from combined oral and topical male-partner treatment, but this evidence postdates current CDC guidelines and represents emerging rather than established practice.
Interventions That Do NOT Work in Pessary Users
TrimoSan gel (hydroxyquinoline-based) applied twice weekly does not reduce bacterial vaginosis prevalence (24% versus 23% at 3 months, P=0.82) or vaginal symptoms in pessary users. 6
Vaginal probiotic suppositories do not alter vaginal microenvironment composition, lactobacilli counts, or symptom burden after 3 months of use in pessary users. 7
Critical Pitfalls to Avoid
Do not remove the pessary to treat bacterial vaginosis; standard antimicrobial therapy is effective with the device in place. 2, 1
Do not use single-dose metronidazole 2 g as first-line therapy due to its inferior 84% cure rate. 1
Do not prescribe vaginal metronidazole to patients with oral metronidazole allergy due to cross-reactivity risk. 1
Do not assume that adjunctive vaginal gels or probiotics will prevent bacterial vaginosis in pessary users; evidence shows no benefit. 6, 7
Always counsel complete alcohol abstinence during metronidazole therapy and for 24 hours afterward to prevent severe disulfiram-like reactions. 1
Special Consideration: Pre-Procedural Prophylaxis
- If a pessary user requires surgical abortion or hysterectomy, screen and treat bacterial vaginosis before the procedure because treatment with metronidazole substantially reduces postoperative infectious complications (10–75% reduction). 2